The kinetics of cytomegalovirus (CMV) DNA in infected asymptomatic hosts are largely unknown. We measured viral load (VL) in 124 fluid samples (oral, urine, vaginal, blood) collected from 21 women who acquired CMV. A quantitative realtime polymerase chain reaction assay of US17, which correlated with clinical assays, was used. VL decreased following primary infection in all fluids. The geometric mean VL of vaginal fluid was significantly higher than that of other sources: oral (3.89; 95% confidence interval [CI], 1.43-10.57), urine (6.36; 95% CI, 2.48-16.32), and whole blood (11.88; 95% CI,. Vaginal CMV shedding may provide a route for sexual and possibly perinatal transmission.
The kinetics of cytomegalovirus (CMV) DNA in infected asymptomatic hosts are largely unknown. We measured viral load (VL) in 124 fluid samples (oral, urine, vaginal, blood) collected from 21 women who acquired CMV. A quantitative realtime polymerase chain reaction assay of US17, which correlated with clinical assays, was used. VL decreased following primary infection in all fluids. The geometric mean VL of vaginal fluid was significantly higher than that of other sources: oral (3.89; 95% confidence interval [CI], 1.43-10.57), urine (6.36; 95% CI, 2.48-16.32), and whole blood (11.88; 95% CI, 4.12-34.20).
Vaginal CMV shedding may provide a route for sexual and possibly perinatal transmission.
Keywords. Cytomegalovirus; viral loads; normal host; US17 real-time PCR.
Cytomegalovirus (CMV) is ubiquitous and establishes lifelong latency after primary infection [1] . Most infections are asymptomatic and latency is associated with episodic reactivation and viral shedding. Information on viral load (VL) kinetics in normal hosts is limited, and comparative measurements from different body fluids are not available. Congenitally infected children shed virus for several years. Healthy CMV-seropositive children shed CMV in saliva and urine for months. VL in saliva was significantly higher in young infants compared to 2-yearolds [2] . CMV shedding increases with advancing gestation [3] , and shedding from mothers who transmit CMV is prolonged compared to nontransmitters. Higher VL at birth may correlate with symptoms and development of hearing loss.
MATERIALS AND METHODS

Subjects and Samples
A phase 2 vaccine trial of CMV glycoprotein B (gB) provided an opportunity to determine VL kinetics after primary CMV infection [4] . Healthy women who participated in this trial and acquired CMV infection provided samples from multiple body sources for measurement of VL. Samples from 21 randomly selected placebo recipients (from a total of 32) who acquired CMV were collected. All subjects were tested for CMV infection by serology every 3 months. Within 1 month after seroconversion was detected, samples of blood, urine, oral (saliva), and vaginal swabs were collected for polymerase chain reaction (PCR) assay. Follow-up samples were collected through the 3.5 years of the study. Vaginal and oral specimens were collected with sterile Dacron swabs and placed in transport media. Samples were stored at -80° until testing by quantitative realtime PCR. Institutional review board approval was obtained at the University of Alabama and at Johns Hopkins University School of Medicine.
Laboratory Methods
DNA Extraction
CMV DNA was extracted from 400 μL of urine, oral, and vaginal fluids using the BioRobot M48 with the MagAttract Virus Mini M48 kit (Qiagen, Valencia, California). Whole blood was extracted from 200 μL using the manual QIAmp Blood Mini Kit (Qiagen).
US17 Real-time PCR
The quantitative CMV real-time PCR assay is based on detection of a 151-bp region from the US17 gene [5] . US17 modulates host pathways at early and late times of infection to enable production of virions [6] . The assay limit of detection is 100 copies/mL (4 copies/reaction) and the measureable range is 2.0-8.0 log 10 copies/mL for both plasma and urine. Intra-and interrun precision at 2.0 log 10 copies/mL in plasma and urine yielded standard deviations of 0.08 and 0.24 with percentage coefficient of variations of 4.2 and 11.8, respectively. The assay has been reported and details are provided in the Supplementary Materials [7] .
Statistical Methods
Descriptive displays and statistics were used to examine patterns in VL measurements by body source and time. Time periods were defined as follows: T1, all samples collected within 1 month of documented seroconversion, through day 90; and T2, all samples collected beyond day 90. If any individual had >1 sample for a particular body source within a given time period, the geometric mean of those samples was used. Due to their skewed nature, VL measurements were logarithmically transformed prior to analysis; 10 copies/mL was added to each measurement with undetectable VL prior to transformation. For each source of body fluid, a nonparametric trend test was used to determine if VL differed by time. A mixed model was used to estimate the differences in log(VL) by source, adjusted for time period. The difference in log(VL) between sources, as estimated by the regression coefficient (β), was exponentiated (e β ) for interpretation purposes and represents the ratio of the VL between the geometric mean VL of one source vs the other source. We further examined if there was an interaction between time period and body fluid source on VL. Figure 1A ). There was no significant difference between mean US17 values and mean artus values (mean difference, -0.05 log 10 copies/mL; 95% CI, -.13 to .02 log 10 copies/mL). An analysis of the difference between artus and US17 real-time PCR demonstrated minor variability (standard deviation [SD], 0.32 log 10 copies/mL). Most results (74/77) fell within 2 SD from the mean difference (Supplementary Figure 1B) . Similarly, correlation between US17 and CAP/CTM48 demonstrated that the methods were linearly related (slope = 1.04; 95% CI, .96-1.12) and correlated (r = 0.95; 95% CI, .92-.97; Supplementary Figure 1C ). Values obtained with US17 real-time PCR showed only a slight difference in quantification from CAP/CTM48 with a mean difference of 0.05 log 10 copies/mL (95% CI, -.04 to .16 log 10 copies/mL). An analysis of the difference between CAP/CTM48 and US17 demonstrated a higher degree of variability (SD, 0.44 log 10 copies/mL) than that estimated between artus and US17. Most results (72/76) fell within 2 SD from the mean difference (Supplementary Figure 1D) . In summary, an excellent correlation was confirmed between the US17 and the clinical assays on plasma samples.
RESULTS
US17
Samples Collected From Healthy Women
The study cohort included healthy women from the Birmingham Alabama Metropolitan area, aged 14-40 years (median, 19.6 years), who were enrolled in the CMV vaccine trial. CMVseronegative women were invited to participate in the clinical trial. Most of the study population was African American (75%). Across 21 randomly selected women, 124 samples (oral, n = 31; urine, n = 35; vaginal, n = 28; and whole blood, n = 30) were collected. Two women contributed only 1 sample from any source, 2 women had 2 samples each, 3 women had 4 samples, 4 women had 5 samples, 3 women had 7 samples, 3 women had 8 samples, 2 women had 9 samples, 1 woman had 11 samples, and 1 woman had 12 samples, with a median of 5 samples per woman. If >1 sample per source per woman was provided at either T1 or T2, the geometic mean of the VL in those samples was used, resulting in a total of 97 analytic observations. In T1, the analysis included 15 oral, 18 urine, 15 vaginal, and 11 whole-blood samples. Beyond 90 days, samples included 9 oral, 11 urine, 10 vaginal, and 8 whole blood.
Distribution of VL by Body Fluid
The kinetics of VL in each body fluid and differences in VL between fluids were determined. Based on a nonparametric trend test, VL decreased over time in oral and vaginal fluid ( Table 1) . At T1 (days 0-90), VL in vaginal fluids was higher than VL in other fluids ( Figure 1A) ; therefore, VL in vaginal fluids was compared to all other body fluids at T1 and T2 ( Figure 1A and 1B). For each tested time period, vaginal fluid VL was statistically different from all other fluids. A mixedmodel regression analysis of log-transformed VL was performed to test for the pattern of VL changes over time across all body sources. In the time-period adjusted analysis, there were significant differences in VL between sources: The geometric mean VL in urine was 0.61 times that in oral samples (95% CI, .23-1.61); VL in whole blood was 0.33 times that of the oral VL (95% CI, .11-.97) and 0.54 times that of the urine VL (95% CI, .19-1.50). Geometric mean VL in vaginal fluids was consistently higher than VL in any other fluid: 3.89 times higher than the oral VL (95% CI, 1.43-10.57), 6.36 times higher than the urine VL (95% CI, 2.48-16.32), and 11.88 times higher than the whole-blood VL (95% CI, 4.12-34.20).
Discussion
In this study, CMV DNA was quantified in multiple body fluids from healthy women using a US17 real-time PCR. VLs were higher in vaginal fluid compared to other fluids at the tested time periods and decreased following primary infection in all body fluids.
Data on CMV VL in the normal hosts are limited compared to the plethora of information available from Whole blood 11 <100 <100-<100 8 <100 <100-<100
Values are expressed as copies/mL. VL <100 copies/mL was detected but not quantifiable. The total number of analytic observations is 97; the geometric mean titer was computed whenever a woman provided >1 sample from the same source during a time period.
Abbreviations: IQR, interquartile range; T1, samples collected within 1 month of seroconversion, through day 90; T2, samples collected beyond day 90; VL, viral load.
immunocompromised populations. Understanding VL kinetics in normal hosts may provide insights into CMV biology and pathogenesis. However, identification of asymptomatic patients with primary CMV infection and sample collection from this population poses a challenge. A study of 6 adolescents with primary CMV infection who were followed up for a median of 5.5 months revealed that CMV was detected intermittently from urine, cervical secretions, and white blood cells, and that CMV DNA in white blood cells decreased over time, based on qualitative gB PCR [8] .
Vaginal shedding of CMV plays an important role in maintaining the prevalence of infection and can have clinical significance in specific situations. CMV persistence in the female genital tract facilitates sexual transmission, an important source of CMV infection in sexually active adolescents and adults. In a study of 347 women attending a sexually transmitted disease clinic, CMV seropositivity was associated with lifetime number of sex partners, young age at first sexual intercourse, and nonwhite race [9] .
CMV shedding in the genital tract is common in seropositive pregnant women; rates of 10%-30% were reported using viral culture, with the higher rates late in pregnancy [10] . Transmission of CMV to the newborn occurs approximately 50% of the time when the virus is present in the maternal genital tract at delivery [11] . Newborns with intrapartum CMV infection will shed virus, which can be spread to caregivers and other children. Perinatal CMV in healthy term infants is usually not associated with severe CMV disease. However, CMV acquisition near delivery of very low birth weight premature newborns has been associated with acute systemic illness with respiratory failure and hematological and liver function abnormalities [12] . In human immunodeficiency virus (HIV)-infected women, transmission of CMV from mother to newborn is common, even among formula-fed newborns (ruling out breast-milk transmission), and CMV coinfection has been associated with more rapid progression to HIV disease in infants [13] . Vaginal shedding of CMV (detected by real-time PCR of gB) in healthy pregnant women has been associated with an increased miscarriage rate, suggesting that CMV in the genital tract could result in adverse pregnancy outcomes. Of 848 women, 60 (7.1%) were CMV positive. CMV carriers had an increased miscarriage rate (relative risk, 6.96; 95% CI, 2.04-23.84; P < .01) [14] .
Our findings reveal that CMV VL is highest in the vaginal compartment around seroconversion, and then steadily declines in all body sources. The finding of significantly higher VL in vaginal fluid may suggest that certain cells in the genital tract are capable of producing and releasing large quantities of CMV DNA. CMV replication in the vaginal compartment may not be as tightly controlled by CMV-specific immunity as in other compartments or may circumvent immune recognition (similar to human papillomavirus), generating relatively high levels of CMV DNA.
Limitations of our study include the inability to more precisely define the timing of primary CMV infection, and the relatively small sample size. As per protocol, participants' visits during the vaccine trial were set at 3-month intervals. Studies that capture primary CMV infection within a narrower time frame in the normal host are currently nonexistent and are unlikely to be performed. Although the sample size of this study was small, our statistical analysis accounted for repeated measurements across different time periods and sample sources from the same individual using a mixed-model regression approach. The US17 assay was previously compared to real-time PCR assays based on UL65, immediate early protein, and gB in transplant patients. US17 could detect CMV earlier than the gB-based assay and its sensitivity was improved compared with the other assays [15] . The assay has been used extensively in our laboratory, and its performance characteristics have been well-established [7] . We also show high correlation between US17 real-time PCR and the clinical assays on plasma samples. Based on our experience with different sample types, we believe the US17 is well-suited for testing body fluids other than plasma. In summary, shedding of CMV DNA can be measured in multiple body fluids following primary infection. Vaginal CMV shedding is higher than shedding from other fluids, providing modes of transmission during sexual activity and delivery.
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